Gastrointestinal Cancer News

Lymph node status served as the only independent OS predictor after surgery and chemotherapy for patients with esophagogastric cancer, according to a secondary analysis of a phase 3 trial.

Short sleep duration and frequent snoring prior to cancer diagnosis may shorten OS among postmenopausal women with breast cancer.

Patients with large colorectal polyps presented with a lower incidence of cancer than previously thought, leading researchers to conclude that colon-sparing advanced endoscopic techniques should be considered over traditional bowel resection in these patients, according to the results of a retrospective study.

Women with a history of cervical intraepithelial neoplasia 2 or 3 arising from HPV infection appeared to have an increased risk for developing anal, vaginal and vulvar cancers, according to the results of a national cohort study.

ARQ 087, a multi-kinase inhibitor designed to inhibit fibroblast growth factor receptor, displayed a favorable safety profile when administered as monotherapy to patients with intrahepatic cholangiocarcinoma, according to data presented at the European Society of Medical Oncology 18th World Congress on Gastrointestinal Cancer.

Patients with pancreatic cancer who initiated chemotherapy more than 12 weeks following resection appeared to experience similar survival as patients who initiated chemotherapy earlier, according to the results of a retrospective study.

PHILADELPHIA — Fox Chase Cancer Center today hosted a Regional Cancer Moonshot Summit in conjunction with the National Cancer Moonshot Summit held in Washington, D.C., marking the first time that stakeholders representing all cancer types convened under one national charge.

Philadelphia-based Atlantic Diagnostic Laboratories has launched PolypDx, a noninvasive urine test that detects precancerous adenomatous colorectal polyps, according to a press release.

Nancy E. Davidson, MD, director of University of Pittsburgh Cancer Institute, took over as president of the American Association for Cancer Research this spring.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation, has been named acting director of the agency’s new Oncology Center of Excellence.